Neoplastic immune mimicry potentiates breast tumor progression

Area of Science:

• Oncology
• Cell Biology
• Immunology

Background:

• Breast cancer progression involves dedifferentiation, increasing tumor cell adaptability and aggressiveness.
• This cellular plasticity correlates with resistance to therapies and enhanced metastatic potential.

Purpose of the Study:

• To identify and characterize a novel cellular program in neoplastic breast epithelial cells termed "immune mimicry."
• To investigate the association of immune mimicry with breast cancer aggressiveness, treatment resistance, and clinical outcomes.

Main Methods:

• Analysis of single-cell RNA-seq datasets from human breast tumors.
• Histopathological examination of breast tumor specimens.
• In vitro studies using breast cancer cell lines and in vivo studies using murine cancer models.
• Assessment of chemotherapy-induced changes in epithelial cells.

Main Results:

• Subpopulations of dedifferentiated breast cancer cells express leukocyte cell surface receptors, exhibiting "immune mimicry."
• Immune-mimicked cells show hallmarks of dedifferentiation and are prevalent in high-grade, treatment-resistant tumors.
• Cytotoxic chemotherapy treatment induced immune mimicry in aggressive breast cancer cell lines.
• Expression of CD69 (a leukocyte activation protein) by neoplastic cells conferred a proliferative advantage.

Conclusions:

• Neoplastic breast epithelial cells upregulating leukocyte surface receptors potentiate malignancy.
• Immune mimicry is associated with aggressive breast cancer phenotypes, including therapeutic resistance and metastatic potential.
• Neoplastic immune mimicry warrants evaluation for prognostic utility in stratifying breast cancer patients at high risk.